NEWS

Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.1

Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.

Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health. The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.¹

Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical studies demonstrating the ability of a MF59^® adjuvanted influenza vaccine to increase immune responses when used in both seasonal and pandemic influenza vaccines.

CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world’s largest influenza vaccines providers.

This news release is intended for business and trade media only.

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

This news release is intended for Health Professional media only.

Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA^® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older, ¹ extending the company's broad portfolio of influenza vaccine offerings. The approval also applies to the trivalent formulation of AFLURIA® (Influenza Vaccine).²

New studies highlight health and economic benefits of adjuvanted trivalent influenza vaccine amongst two at-risk populations – 65 years+ and young children

Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compared with cell-derived vaccine viruses. The results are reported from a retrospective analysis that evaluated the degree of match between circulating influenza viruses and candidate viruses that were derived from egg-based and cell-based technologies over multiple influenza seasons.¹

Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2018-2019 influenza season. Seqirus, one of the largest influenza vaccine companies in the world, and a leading innovator of new technologies, expects to distribute over 50 million doses to the U.S. market this year.

Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina. The approval will enable Seqirus to more than double current production levels of FLUCELVAX® QUADRIVALENT for supply in the 2019/20 influenza season.

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older

Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in individuals five years of age and older, extending the company’s broad portfolio of influenza vaccine offerings. AFLURIA QUADRIVALENT, which was first approved in the U.S. on August 2016 for individuals 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.^3,10

As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services (DHHS), has requested urgent support to help displaced residents fight the onset of influenza.

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season.

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.